26 September 2019 | News
Daptomycin for Injection, 500mg/vial, single-dose vial for intravenous use only
image credit- istock.com
Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), The pharmaceuticals and drug company, announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.
According to IQVIA (IMS Health), Cubicin® for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019. The product is available for shipping immediately.